World's Best Scientists 2026 revealed!
Jeffrey Crawford

Jeffrey Crawford

D-Index & Metrics

Medicine

D-Index
84
Citations
32083
World Ranking
14927
National Ranking
7545

Jeffrey Crawford publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jeffrey Crawford sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 473 publications — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jeffrey Crawford D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey Crawford sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jeffrey Crawford is affiliated with Duke University in the United States and has contributed extensively to the field of medicine, focusing primarily on oncology. Their research encompasses a broad spectrum of topics related to cancer treatment and patient care, with a particular emphasis on chemotherapy effects, lung cancer, and biomarkers associated with cancer progression and cachexia.

Their publication record includes significant papers such as:

  • Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis (2021, The Oncologist)
  • Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? (2022, The Oncologist)
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) (2021, Journal for ImmunoTherapy of Cancer)
  • A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia (2023, Clinical Cancer Research)
  • Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life (2021, Patient Preference and Adherence)

Crawford's frequent co-authors include Jeffrey Clarke, Michelle I. Rossulek, Thomas E. Stinchcombe, Richard F. Dunne, and Scott Antonia, reflecting collaborative work predominantly in oncology-related studies.

The primary venues for their publications are:

  • Journal of Clinical Oncology
  • Journal of Cachexia Sarcopenia and Muscle
  • The Oncologist
  • Supportive Care in Cancer
  • Lung Cancer

Their main field of study is medicine, with subfields concentrating on:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Physiology
  • Genetics
  • Molecular Biology

Within these fields, Crawford's research addresses topics such as:

  • Neutropenia and Cancer Infections
  • Nutrition and Health in Aging
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Lung Cancer Research Studies
  • GDF15 and Related Biomarkers
  • Cancer Immunotherapy and Biomarkers

Their work notably explores clinical challenges in managing chemotherapy-induced side effects like neutropenia and myelosuppression, as well as investigating therapeutic approaches to lung cancer resistant to immune checkpoint inhibitors. Another area of focus involves cancer cachexia and associated biomarkers, contributing to understanding pathological mechanisms and treatment strategies.

Best Publications

  • Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

    Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford

  • Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

    Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson

  • 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

    Thomas J. Smith;James Khatcheressian;Gary H. Lyman;Howard Ozer

  • 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*

    Thomas J. Smith;Howard Ozer;Langdon L. Miller;Charles A. Schiffer

  • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy : A systematic review

    Nicole M. Kuderer;David C. Dale;Jeffrey Crawford;Gary H. Lyman

  • Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

    Thomas J. Smith;Kari Bohlke;Gary H. Lyman;Kenneth R. Carson

  • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

    B J Roth;D H Johnson;L H Einhorn;L P Schacter

  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

    Matti Aapro;David A Cameron;Ruth Pettengell;Julia Bohlius

  • Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices

    Gary H. Lyman;David C. Dale;Jeffrey Crawford

  • Sarcopenia: A Time for Action. An SCWD Position Paper.

    Juergen Bauer;John E. Morley;Annemie M.W.J. Schols;Luigi Ferrucci

  • Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

    Jeffrey Crawford;David Cella;Charles S. Cleeland;Pierre Yves Cremieux;Pierre Yves Cremieux

  • Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431

    Everett E. Vokes;James E. Herndon;Jeffrey Crawford;Kenneth A. Leopold

  • Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study

    Gary H. Lyman;David C. Dale;Jonathan Friedberg;Jeffrey Crawford

  • Effects of Polyethylene Glycol–Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts after Chemotherapy for Lung Cancer

    Michael Fanucchi;John Glaspy;Jeffrey Crawford;Jennifer Garst

  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.

    Eileen Johnston;Jeffrey Crawford;Susan Blackwell;Toni Bjurstrom

  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

    R.N. Patricia J. Hollen Ph.D.;Richard J. Gralla;Mark G. Kris;Christopher Cox

  • Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

    Pasi A. Jänne;Xiaofei Wang;Mark A. Socinski;Jeffrey Crawford

  • Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

    Kenneth A. Foon;Xiao Dong Yang;Louis M. Weiner;Arie S. Belldegrun

  • Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

    J Glaspy;J Crawford;Johan Vansteenkiste;D Henry

  • Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy

    Gary H. Lyman;Vicki A. Morrison;David C. Dale;Jeffrey Crawford

Frequent Co-Authors

Gary H. Lyman
Gary H. Lyman Fred Hutchinson Cancer Research Center
David C. Dale
David C. Dale University of Washington
James E. Herndon
James E. Herndon Duke University
John A. Glaspy
John A. Glaspy University of California, Los Angeles
Harvey J. Cohen
Harvey J. Cohen Duke University
Everett E. Vokes
Everett E. Vokes University of Chicago
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Thomas A. D'Amico
Thomas A. D'Amico Duke University
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing a medical degree is a rewarding path, there are several related online programs that can expand your career opportunities in healthcare. Many students consider obtaining a masters in healthcare administration cost degree to move into leadership and management roles within hospitals and clinics. This degree equips you with financial, operational, and strategic skills crucial for modern healthcare systems.

For nurses seeking to advance their clinical expertise or assume higher responsibilities, exploring the best dnp programs online can be an excellent next step. Doctor of Nursing Practice (DNP) degrees are ideal for those interested in advanced practice, leadership, or specialized research roles.

The pharmaceutical field is another fast-growing industry. Accredited online pharmacy programs are designed for those aspiring to become pharmacists without the limitations of on-campus programs, providing flexibility and affordability.

With healthcare technology evolving rapidly, a bachelor of health information management online opens doors to careers in data management, informatics, and health IT. These roles are critical to ensuring patient information is secure, accurate, and efficiently managed.

Best Scientists Citing Jeffrey Crawford

Trending Scientists

Recently Published Articles